Researchers at KTH Royal Institute of Technology have developed a bran-based hydrogel designed to deliver therapeutic drugs directly to the colon.
By utilizing arabinoxylan fibers extracted from wheat and rye bran, the team aims to improve the precision of treatments for conditions like ulcerative colitis and colorectal cancer.
Clinical Potential of Bran-Derived Delivery
- Targeted Release: Unlike standard coatings that rely on pH levels, these gels use gut bacteria to trigger drug release, potentially reducing systemic side effects.
- Natural Biomaterials: The hydrogel is constructed from agricultural side streams, making it a sustainable and biodegradable option for repeated medical use.
- Customizable Performance: Techniques such as freeze-drying allow researchers to tune the gel’s structure, ensuring the encapsulated protein remains stable during transit.
Engineered Hydrogels for Targeted Therapy
Current drug delivery systems for lower intestinal diseases often struggle with premature release. Most conventional medications are encased in polymers designed to dissolve at a pH of 7. However, individual variations in digestive enzymes, fluid volumes, and stomach acidity can cause these coatings to break down before reaching the colon, according to research published by the KTH Royal Institute of Technology.
To overcome these variables, the research team focused on β-xylanase, an enzyme produced by native colon bacteria. This enzyme naturally breaks down plant fibers. By creating a hydrogel from arabinoxylan—a fiber found in wheat and rye bran—the scientists engineered a material that remains intact until it encounters the specific bacterial environment of the colon.
“We believe this could one day have applications for oral delivery of drugs or probiotics to the gut, for example to treat inflammatory symptoms, said Francisco Vilaplana, Director of the PLENTY Research Center and Professor in Glycoscience at KTH Royal Institute of Technology.”
Rye-Based Gels Effectively Retain Model Proteins in Testing
The research team, which includes PhD student Carl Rämgård and Associate Professor Lauren McKee, tested the hydrogel’s ability to retain model proteins. Their findings indicated that rye-based arabinoxylan (RAX) gels were particularly effective at holding these molecules until triggered by the bacterial enzyme.
While the laboratory results are promising, the long-term behavior of these gels remains under investigation. Researchers have not yet confirmed if the structure can survive the initial stages of digestion, including the harsh environment of the stomach and the small intestine. Further in vivo testing—studies conducted within a living organism—is required to validate the transit stability of the hydrogel.
| Feature | Standard pH-Dependent Coatings | Bran-Based Hydrogel |
|---|---|---|
| Trigger Mechanism | Acidity (pH level) | Bacterial enzyme (β-xylanase) |
| Primary Material | Synthetic/Chemical Polymers | Natural plant fiber (Arabinoxylan) |
| Reliability | Variable due to gastric acid | Dependent on colonic microbiome |
Experimental Technology Requires Clinical Trials and Medical Consultation
This technology is currently in the experimental phase and is not yet available for clinical use. Patients managing chronic conditions such as Crohn’s disease or ulcerative colitis should not alter their current treatment regimens based on this research. Any new therapeutic delivery system will require rigorous clinical trials to ensure safety, efficacy, and the absence of allergic reactions to plant-based fibers.
Consult a gastroenterologist if you experience persistent abdominal pain, unexplained weight loss, or changes in bowel habits. These symptoms require professional diagnostic evaluation to rule out active inflammation or malignancy, which are currently treated with established, FDA-approved therapies.
Svenska Forskningsrådet and PLENTY Centre Support Research Development
The research was supported by the Svenska Forskningsrådet (Formas) and the PLENTY Centre for Circular and Symbiotic Food Provisioning. By bridging agricultural byproducts with pharmaceutical engineering, the team aims to develop cost-effective, degradable materials for long-term gut health management.
Future studies will likely focus on the structural integrity of the gel during gastrointestinal transit. As the technology matures, it may provide a more reliable, personalized approach to delivering medications or probiotics directly to the site of intestinal disease.
References
- Researchers at KTH Royal Institute of Technology have tested the concept of using bran-based hydrogels for encapsulating potential colon treatments.
